Abstract
Fibrillar amyloid beta-protein (Aβ) is a major component of amyloid plaques in the brains of individuals with Alzheimer’s disease (AD) and of adults with Down syndrome (DS). Gelsolin, a cytoskeletal protein, is present both intracellularly (cytoplasmic form) and extracellularly (secretory form in biological fluids). These two forms of gelsolin differ from each other in length and in cysteinyl thiol groups. Previous studies from our and other groups have identified the anti-amyloidogenic role of gelsolin in AD. Our studies showed that both plasma and cytosolic gelsolin bind to Aβ, and that gelsolin inhibits the fibrillization of Aβ and solubilizes preformed fibrils of Aβ. Other studies have shown that peripheral administration of plasma gelsolin or transgene expression of plasma gelsolin can reduce amyloid load in the transgenic mouse model of AD. Our recent studies showed that gelsolin expression increases in cells in response to oxidative stress. Oxidative damage is considered a major feature in the pathophysiology of AD. Aβ not only can induce oxidative stress, but also its generation is increased as a result of oxidative stress. In this article, we review evidence of gelsolin as an anti-amyloidogenic agent that can reduce amyloid load by acting as an inhibitor of Aβ fibrillization, and as an antioxidant and anti-apoptotic protein.
Similar content being viewed by others
References
Ali FE, Separovic F, Barrow CJ et al (2005) Methionine regulates copper/hydrogen peroxide oxidation products of Abeta. J Pept Sci 11:353–360. doi:10.1002/psc.626
Arlt S, Beisiegel U, Kontush A (2002) Lipid peroxidation in neurodegeneration: new insights into Alzheimer’s disease. Curr Opin Lipidol 13:289–294. doi:10.1097/00041433-200206000-00009
Bandopadhyay U, Dipak D, Banerjee RK (1999) Reactive oxygen species: oxidative damage and pathogenesis. Curr Sci 77:658–666
Behl C (2005) Oxidative stress in Alzheimer’s disease: implications for prevention and therapy. Subcell Biochem 38:65–78. doi:10.1007/0-387-23226-5_3
Chauhan V, Chauhan A (2006) Oxidative stress in Alzheimer’s disease. Pathophysiol 13:195–208. doi:10.1016/j.pathophys.2006.05.004
Chauhan A, Chauhan VPS, Wegiel J et al (1996a) Impact of normal and heat-inactivated serum on in-vitro aggregation and fibrillization of synthetic amyloid beta-protein. Alzheimer’s Res 2:243–248
Chauhan A, Pirttila T, Mehta P et al (1996b) Effect of cerebrospinal fluid from normal and Alzheimer’s patients with different apolipoprotein E phenotypes on in vitro aggregation of amyloid beta-protein. J Neurol Sci 141:54–58. doi:10.1016/0022-510X(96)00123-2
Chauhan A, Chauhan VPS, Rubenstein R et al (1997a) Media from rhabdomyosarcoma and neuroblastoma cell cultures stimulate in vitro aggregation and fibrillization of amyloid beta-protein. Neurochem Res 22:227–232. doi:10.1023/A:1027379926976
Chauhan VPS, Ray I, Chauhan A et al (1997b) Metal cations defibrillize the amyloid beta-protein fibrils. Neurochem Res 22:805–809. doi:10.1023/A:1022079709085
Chauhan VPS, Ray I, Chauhan A et al (1999) Binding of gelsolin, a secretory protein, to amyloid β-protein. Biochem Biophys Res Commun 258:241–246. doi:10.1006/bbrc.1999.0623
Dikalov SI, Vitek MP, Mason RP (2004) Cupric-amyloid beta peptide complex stimulates oxidation of ascorbate and generation of hydroxyl radical. Free Radic Biol Med 36:340–347. doi:10.1016/j.freeradbiomed.2003.11.004
Eun DW, Ahn SH, You JS et al (2007) PKC epsilon is essential for gelsolin expression by histone deacetylase inhibitor apicidin in human cervix cancer cells. Biochem Biophys Res Commun 354:769–775. doi:10.1016/j.bbrc.2007.01.046
Forloni G (1996) Neurotoxicity of beta-amyloid and prion peptides. Curr Opin Neurol 9:492–500. doi:10.1097/00019052-199612000-00017
Furukawa K, Fu W, Li Y et al (1997) The actin-severing protein gelsolin modulates calcium channel and NMDA receptor activities and vulnerability to excitotoxicity in hippocampal neurons. J Neurosci 17:8178–8186
Gabbita SP, Lovell MA, Markesbery WR (1998) Increased nuclear DNA oxidation in the brain in Alzheimer’s disease. J Neurochem 71:2034–2040
Ghiso J, Matsubara E, Koudinov A et al (1993) The cerebrospinal fluid soluble form of Alzheimer’s amyloid β is complexed to SP-40, 40 (APO J), an inhibitor of the complement membrane attack complex. Biochem J 293:27–30
Glenner GG (1983) Alzheimer’s disease: the commonest form of amyloidosis. Arch Pathol Lab Med 107:281–282
Golabek AA, Soto C, Vogel T et al (1996) The interaction between apolipoprotein E and Alzheimer’s amyloid beta-peptide is dependent on beta-peptide conformation. J Biol Chem 271:10602–10606. doi:10.1074/jbc.271.52.33623
Haass C, Schlossmacher MG, Hung AY et al (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359:322–325. doi:10.1038/359414a0
Hartley DM, Walsh DM, Ye CP et al (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19:8876–8884
Hilbich C, Kisters-Woike B, Reed J et al (1991) Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer’s disease. J Mol Biol 218:149–163. doi:10.1016/0022-2836(91)90881-6
Hirko AC, Meyer EM, King MA et al (2007) Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of Alzheimer’s disease. Mol Ther 15:1623–1629. doi:10.1038/sj.mt.6300253
Iversen LL, Mortishire-Smith RJ, Pollack SJ et al (1995) The toxicity in vitro of β-amyloid protein. Biochem J 311:1–16
Jang JH, Surh YJ (2004) Possible role of NF-kappaB in Bcl-X(L) protection against hydrogen peroxide-induced PC12 cell death. Redox Rep 9:343–348. doi:10.1179/135100004225006858
Janmay PA (1994) Phosphoinositides and calcium as regulators of cellular actin assembly and disassembly. Annu Rev Physiol 56:169–191
Jhoo JH, Kim HC, Nabeshima T et al (2004) Beta-amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav Brain Res 155:185–196. doi:10.1016/j.bbr.2004.04.012
Ji L, Chauhan A, Chauhan V (2008) Cytoplasmic gelsolin in pheochromocytoma-12 cells forms a complex with amyloid beta-protein. Neuroreport 19:463–466
Kang J, Lemaire HG, Unterbeck A et al (1987) The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733–736. doi:10.1038/325733a0
Kim HC, Yamada K, Nitta A (2003) Immunocytochemical evidence that amyloid beta (1-42) impairs endogenous antioxidant systems in vivo. Neuroscience 119:399–419. doi:10.1016/S0306-4522(02)00993-4
Kirkitadze MD, Kowalska A (2005) Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer’s disease. Acta Biochim Pol 52:417–423
Kothakota S, Azuma T, Reinhard C et al (1997) Caspase-3-generated fragment of gelsolin: effector of morphological changes in apoptosis. Science 278:294–298. doi:10.1126/science.278.5336.294
Koudinov A, Matsubara E, Frangione B et al (1994) The soluble form of Alzheimer’s amyloid beta-protein is complexed to high-density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 205:1164–1171. doi:10.1006/bbrc.1994.2788
Kuzumaki N, Tanaka M, Sakai N et al (1997) Tumor suppressive function of gelsolin. Gan To Kagaku Ryoho 24:1436–1441
Kwiatkowski DJ, Mehl R, Ying HL (1988) Genomic organization and biosynthesis of secreted and cytoplasmic forms of gelsolin. J Cell Biol 106:375–384. doi:10.1083/jcb.106.2.375
Lambert MP, Barlow AK, Chromy BA et al (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448–6453. doi:10.1073/pnas.95.11.6448
Levy E, Carman MD, Fernandez-Madrid IJ et al (1990) Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248:1124–1126. doi:10.1126/science.2111584
Lorenzo A, Yanker BA (1994) β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 91:12243–12247. doi:10.1073/pnas.91.25.12243
Lovell MA, Gabbita SP, Markesbery WR (1999) Increased DNA oxidation and decreased levels of repair products in Alzheimer’s disease ventricular CSF. J Neurochem 72:771–776. doi:10.1046/j.1471-4159.1999.0720771.x
Lyras L, Cairns NJ, Jenner A et al (1997) An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer’s disease. J Neurochem 68:2061–2069
McDonagh B, Sheehan D (2007) Effect of oxidative stress on protein thiols in the blue mussel Mytilus edulis: proteomic identification of target proteins. Proteomics 7:3395–3403. doi:10.1002/pmic.200700241
Masters CL, Simms G, Weinman NA et al (1985) Amyloid plaque core protein in Alzheimer’s disease and Down’s syndrome. Proc Natl Acad Sci USA 82:4245–4249. doi:10.1073/pnas.82.12.4245
Markesbery WR, Carney JM (1999) Oxidative alterations in Alzheimer’s disease. Brain Pathol 9:133–146
Matsumoto N, Kitayama H, Kitada M et al (2003) Isolation of a set of genes expressed in the choroid plexus of the mouse using suppression subtractive hybridization. Neuroscience 117:405–415. doi:10.1016/S0306-4522(02)00827-8
Matsuoka Y, Saito M, LaFrancois J et al (2003) Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23:29–33
Maury CP, Sletten K, Totty N et al (1997) Identification of the circulating amyloid precursor and other gelsolin metabolites in patients with G654A mutation in the gelsolin gene (Finnish familial amyloidosis): pathogenetic and diagnostic implications. Lab Invest 77:299–304
Mazur-Kolecka B, Kowal D, Sukontasup T et al (2003) The effect of oxidative stress on accumulation of apolipoprotein E3 and E4 in a cell culture model of beta-amyloid angiopathy (CAA). Brain Res 983:48–57. doi:10.1016/S0006-8993(03)03026-9
Mohmmad AH, Wenk GL, Gramling M et al (2004) APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer’s disease. Neurosci Lett 368:148–150. doi:10.1016/j.neulet.2004.06.077
Murphy B, Kirszbaum L, Walker I et al (1988) SP-40, 40, a newly identified normal human serum protein found in SC5b-9 complex of complement and in the immune deposits in glemerulonephritis. J Clin Invest 81:1858–1864. doi:10.1172/JCI113531
Park L, Anrather J, Forster C et al (2004) Abeta-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J Cereb Blood Flow Metab 24:334–342. doi:10.1097/01.WCB.0000105800.49957.1E
Paunio T, Kiuru S, Karonen S et al (1994) Quantification of gelsolin in the serum of familial amyloidosis, Finnish type (Agel). Amyloid Int J Exp Clin Invest 1:80–89
Pitas R, Boyles J, Lee S et al (1987) Lipoproteins and their receptors in the central nervous system, characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E (LDL) receptors in the brain. J Biol Chem 262:14352–14360
Qiao H, Koya RC, Nakagawa K (2005) Inhibition of Alzheimer’s amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin. Neurobiol Aging 26:849–855. doi:10.1016/j.neurobiolaging.2004.08.003
Ray I, Chauhan A, Wegiel J et al (2000) Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Brain Res 853:344–351. doi:10.1016/S0006-8993(99)02315-X
Sastre M, Steiner H, Fuchs K et al (2001) Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2:835–841. doi:10.1093/embo-reports/kve180
Schuessel K, Schafer S, Bayer TA et al (2005) Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol Dis 18:89–99. doi:10.1016/j.nbd.2004.09.003
Serpell LC, Sunde M, Benson MD et al (2000) The protofilament substructure of amyloid fibrils. J Mol Biol 300:1033–1039. doi:10.1006/jmbi.2000.3908
Seubert P, Vigo-Pelfrey C, Esch F et al (1992) Isolation and quantitation of soluble Alzheimer’s beta-peptide from biological fluids. Nature 359:325–327. doi:10.1038/359325a0
Stossel TP (1990) Actin-membrane interactions in eukaryotic mammalian cells. In: Hoffman JF, Giebisch G (eds) Current topics in membranes and transport, vol 36. Academic Press, NY, pp 97–107
Strittmatter WJ, Weisgraber KH, Huang DY et al (1993) Binding of human apolipoprotein E to synthetic amyloid β-peptide: isoform-specific effects and implications for late-onset Alzheimer’s disease. Proc Natl Acad Sci USA 90:8098–8102. doi:10.1073/pnas.90.17.8098
Sultana R, Ravagna A, Mohmmad-Abdul H et al (2005) Ferulic acid ethyl ester protects neurons against amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem 92:749–758. doi:10.1111/j.1471-4159.2004.02899.x
Tamagno E, Robino G, Obbili A et al (2003) H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp Neurol 180:144–155. doi:10.1016/S0014-4886(02)00059-6
Tanaka J, Sobue K (1994) Localization and characterization of gelsolin in nervous tissues: gelsolin is specifically enriched in myelin-forming cells. J Neurosci 14:1038–1052
Vardy ER, Catto AJ, Hooper NM (2005) Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer’s disease. Trends Mol Med 11:464–472. doi:10.1016/j.molmed.2005.08.004
Vassar R, Bennett BD, Babu-Khan S et al (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735–741. doi:10.1126/science.286.5440.735
Vigo-Pelfrey C, Lee D, Keim P et al (1993) Characterization of β-amyloid peptide from human cerebrospinal fluid. J Neurochem 61:1965–1968. doi:10.1111/j.1471-4159.1993.tb09841.x
Vouyiouklis DA, Brophy PJ (1997) A novel gelsolin isoform expressed by oligodendrocytes in the central nervous system. J Neurochem 69:995–1005
Walsh DM, Hartley DM, Kusumoto Y et al (1999) Amyloid beta-protein fibrillogenesis Structure and biological activity of protofibrillar intermediates. J Biol Chem 274:25945–25952. doi:10.1074/jbc.274.36.25945
Wegiel J, Chauhan A, Wisniewski HM et al (1996) Promotion of synthetic amyloid β-peptide fibrillization by cell culture media and abolishment of fibrillization by serum. Neurosci Lett 211:151–154. doi:10.1016/0304-3940(96)12739-7
Wen D, Corina K, Chow EP et al (1996) The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure. Biochemistry 35:9700–9709. doi:10.1021/bi960920n
Wisniewski HM, Wegiel J, Kotula L (1996) Some neuropathology aspects of Alzheimer’s disease and its relevance to other disciplines. Neuropathol Appl Neurobiol 22:3–11. doi:10.1111/j.1365-2990.1996.tb00839.x
Wisniewski T, Ghiso J, Frangione B (1997) Biology of Aβ amyloid in Alzheimer’s disease. Neurobiol Dis 4:313–328. doi:10.1006/nbdi.1997.0147
Wujek JR, Dority MD, Frederickson RC et al (1996) Deposits of Abeta fibrils are not toxic to cortical and hippocampal neurons in vitro. Neurobiol Aging 1:107–113. doi:10.1016/0197-4580(95)02020-9
Younkin SG (1995) Evidence that Aβ 42 is the real culprit in Alzheimer’s disease. Ann Neurol 37:287–288. doi:10.1002/ana.410370303
Yu C, Kim SH, Ikeuchi T et al (2001) Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment gamma. Evidence for distinct mechanisms involved in gamma-secretase processing of the APP and Notch1 transmembrane domains. J Biol Chem 276:43756–43760. doi:10.1074/jbc.C100410200
Acknowledgements
This work was supported in part by the funds from the New York State Office of Mental Retardation and Developmental Disabilities, and by NIH Grant No. AG020992.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chauhan, V., Ji, L. & Chauhan, A. Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer’s disease. Biogerontology 9, 381–389 (2008). https://doi.org/10.1007/s10522-008-9169-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10522-008-9169-z